Filter by: patients
Home > Community Treatment Reports and Side Effects > Activella Treatment Report
What is Activella?

Activella is a brand name of the hormones estradiol and norethindrone. It is used to treat moderate to severe symptoms of menopause; vulvar and vaginal atropy and prevention of postmenopausal osteoporosis. It is available in tablet form and as a transdermal patch.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Other 3 3 Efficacy_major Efficacy_cant_tell
Menopause 2 0
Increase effect of another treatment 1 1 Efficacy_cant_tell
menopausal symptoms 1 1 Efficacy_major
Don't know 1 1 Efficacy_cant_tell
Support hormone balance 1 1 Efficacy_major

See all 3 patients currently taking Activella

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 4

Reported Dosages

  0.5 mg-0.1 mg daily 1 mg-0.5 mg daily
  1 Number of Patients: 1 2 Number of Patients: 2  

Reported Stop Reasons

Why Patients Stopped Taking Activella (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 2   Doctor's advice: 67%
Other 1   Other: 33%

See all 3 patients who’ve stopped taking Activella

Reported Duration See details about how long patients take this treatment ▼

Stopped Taking Activella

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Activella

Always
 3 75%
Usually
 0 0%
Sometimes
 0 0%
Never
 1 25%

Burden

Difficulty being on treatment

Burden of Activella

Very
 0 0%
Somewhat
 0 0%
A little
 0 0%
Not at all
 4 100%

Cost

Paid out of pocket

Cost of Activella

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 1 33%
< $25
 2 67%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 24, 2012.